Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Daccak, Rukan
NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2	Recruiting	3	612	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	12/24	02/25
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis	Recruiting	3	160	Europe, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic	12/24	03/25
NCT05535946: ABTECT - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	06/26
Asamoah, Vivian
NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2	Recruiting	3	612	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	12/24	02/25
NCT05535946: ABTECT - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	06/26
Deprez, Nele
NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2	Recruiting	3	612	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	12/24	02/25
NCT05535946: ABTECT - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	06/26